Study summary · 2024 · Evidence review
Home BP-guided treatment in US telemedicine trials
Home BP-guided treatment improved blood-pressure control relative to clinic-based care.
Summary by Vironix Health · Source review: November 11, 2026
How we select and interpret evidence
Original publication
Sameer Acharya; Gagan Neupane; Austin Seals; Madhav Kc; Dean Giustini; Sharan Sharma; Yhenneko J Taylor; Deepak Palakshappa; Jeff D Williamson; Justin B Moore; Hayden B Bosworth; Yashashwi Pokharel
Cayuga Medical Center; Atrium Health/Wake Forest; Florida Atlantic; Yale; University of British Columbia; SCL Health; Duke University
Hypertension · Online: · Issue: March 2024
Final journal citation; full text checked in PMC and the publisher PDF held by Duke. · Full text consulted.
What was studied
- Design
- Evidence review
- Population
- Adults in US hypertension trials
- Sample
- 13 trials/5,330 participants for systolic BP; 7 trials/3,766 for BP control
- Intervention
- Self-measured BP guiding medication treatment, with variable support
- Comparator
- Clinic-based care
- Follow-up
- At least 6 months
- Review search cutoff
- 2023-07-07
- Setting
- United States
Methods
Random-effects meta-analysis of US randomized trials with subgroup comparisons.
Findings
Systolic BP was lower by 7.3 mmHg (95% CI 5.2–9.4 lower). BP control improved by 10.1 percentage points (95% CI 0.4–19.9).
Limitations
Some trials transmitted readings by mail. Care-team subgroup differences are associations, not randomized component effects; interventions and populations varied.
What this means for care delivery
The evidence supports measurement linked to medication management, not device distribution alone.